States Wrestle Over Measuring The Value Of High-Tech Development

When Walter Plosila was asked in 1982 by Pennsylvania’s Gov. Richard Thomburgh to set up one of the nation’s first state programs to promote high technology, he knew he’d have to show results—and fast. After all, the governor and legislature were putting both personal prestige and taxpayer dollars behind an effort whose linchpin was state-sponsored collaboration between university researchers and industrial entrepreneurs. By February 1987, Plosila was ready to prove

Written byDaniel Charles
| 6 min read

Register for free to listen to this article
Listen with Speechify
0:00
6:00
Share

When Walter Plosila was asked in 1982 by Pennsylvania’s Gov. Richard Thomburgh to set up one of the nation’s first state programs to promote high technology, he knew he’d have to show results—and fast. After all, the governor and legislature were putting both personal prestige and taxpayer dollars behind an effort whose linchpin was state-sponsored collaboration between university researchers and industrial entrepreneurs.

By February 1987, Plosila was ready to prove the program's value: The state’s $120 million investment, he announced, had created or saved 10,664 jobs. In fact, there were numbers galore on what the program had accomplished—including impressive figures on matching private funds raised, patents issued, new companies started, and number of firms that had received assistance. But the key yardstick, Plosila said, was jobs.

The Plosila pitch sounded good, but one year later a state audit declared that his job statistics were “not readily verifiable.” Although no one—even ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies